Patient and physician treatment preferences in atrial fibrillation
“There was a lack of evidence on whether physicians were prescribing anticoagulant treatments with attribute profiles most valued by patients.”
Numerous treatment options are available for nonvalvular atrial fibrillation (NVAF) patients, each offering a different combination of associated attributes, such as stroke risk, bleeding risk, and convenience. There was a lack of evidence on whether physicians were prescribing anticoagulant treatments with attribute profiles most valued by patients.
Conduct a survey of physicians and patients using discrete choice experiment methods to understand the value these stakeholders place on different treatment attributes and the alignment between physicians and patients.
Surveying approximately 200 patients and 200 physicians, PHE assessed how much in monthly copayments participants would be willing to trade for changes in different treatment attributes. The results demonstrated that patients preferred the attribute profile of apixaban to other novel oral anticoagulants. Further, we found that moving from current prescribing practices to ones preferred by patients would reduce the number of strokes in the US by 7540 (8.3%) and would reduce the number of major bleeding events by 14,249 (7.8%) among patients with NVAF.
Within a crowded market of new anticoagulant therapies, the results of the study provided evidence on the advantages of a specific treatment profile, like that of apixaban, that offers lower bleeding risk, lower stroke risk, and greater convenience. The results were published in Value in Health, lending further credibility to the study results.
PHE’s research demonstrated the value of apixaban’s treatment profile compared with that of other anticoagulant therapies.